Document is current

Article History

Received: 25 March 2025

Accepted: 2 June 2025

First Online: 29 June 2025

Declarations

:

: Falk G. Bechara received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie, Acelyrin, Boehringer Ingelheim, Celltrion, Dr. Wolff, Incyte Corporation, Inflarx, Janssen Cilag, Merck, Mölnlycke, MoonLake, Novartis, Sanofi, Sitala, and UCB. Angelo V. Marzano reports consultancy/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Incyte, Bristol Myers Squibb, and UCB. Antonio Martorell has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L’Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squib, Sandoz, and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB, Jansen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, Moonlace, Incyte, and Novartis. Hessel H. van der Zee reports personal fees from AbbVie, InflaRx, Novartis, Galderma, and Incyte. Valeria Jordan M. is an employee and shareholder of Novartis. Nicolas Thomas is an employee and shareholder of Novartis. Ivette Alarcon is an employee and shareholder of Novartis. Axel P. Villani reports personal fees from Abbvie, personal fees from Almirall, personal fees from Amgen, personal fees from BMS, personal fees from Eli Lilly, personal fees from Janssen, personal fees from Leo pharma, personal fees from MSD, personal fees from Novartis, and personal fees from UCB during the conduct of the study. Christos C. Zouboulis has received advisory board and consultation fees from Almirall, Biogen, Boehringer-Ingelheim, CLS Behring, Eli Lilly and Company, Estée Lauder, Idorsia, Incyte, Leo, L’OREAL, MSD, NAOS-BIODERMA, Novartis, PPM, Sanofi, ShiRhom, Takeda, UCB, and ZuraBio and lecture honoraria from Almirall, Amgen, Biogen, BMS, NAOS-BIODERMA, L’Oréal, Novartis, Pfizer, and UCB. His departments have received grants from Astra Zeneca, Boehringer-Ingelheim, BMS, Brandenburg Medical School Theodor Fontane, EADV, European Union, German Federal Ministry of Education and Research, GSK, Incyte, Inflarx, MSD, Novartis, Relaxera, Sanofi, and UCB for his participation as clinical and research investigator. He is president of the EHSF e.V., the Deutsches Register Morbus Adamantiades-Behçet e.V., coordinator of the ALLOCATE Skin group of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin), chair of the ARHS Task Force group of the EADV, and board member of the International Society for Behçet’s Disease. He is editor of the EADV News and co-copyright holder of IHS4 on behalf of the EHSF e.V. John R. Ingram is a consultant for AbbVie, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Incyte, Insmed, Kymera Therapeutics, MoonLake, Novartis, UCB Pharma, UNION therapeutics, and Viela Bio. Until recently, he was the editor-in-chief of the British Journal of Dermatology and receives an authorship honorarium for two UpToDate HS chapters. He is the co-copyright holder of HiSQOL and the Investigator and Patient Global Assessment instruments for HS. His department receives income from the copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. The Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands and the Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany are healthcare providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin).

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.